The diagnostic role and clinical association of serum proteinase 3 anti-neutrophil cytoplasmic antibodies in Chinese patients with inflammatory bowel disease

References

• Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573–621.
   PubMed Web of Science ®Google Scholar
• Farmer M, Petras RE, Hunt LE, et al. The importance of diagnostic accuracy in colonic inflammatory bowel disease. Am J Gastroenterol. 2000;95(11):3184–3188.
   PubMed Web of Science ®Google Scholar
• Mowat C, Cole A, Windsor A, IBD Section of the British Society of Gastroenterology, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60(5):571–607.
   PubMed Web of Science ®Google Scholar
• Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749–753.
   PubMed Web of Science ®Google Scholar
• Lewis James D. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140(6):1817–1826.e2.
   PubMed Web of Science ®Google Scholar
• Bories D, Raynal MC, Solomon DH, et al. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell. 1989;59(6):959–968.
   PubMed Web of Science ®Google Scholar
• Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood. 1997;89(10):3503–3521.
   PubMed Web of Science ®Google Scholar
• Jenne DE. Structure of the azurocidin, proteinase 3, and neutrophil elastase genes. Implications for inflammation and vasculitis. Am J Respir Crit Care Med. 1994;150(6 Pt 2):S147–S154.
   PubMed Web of Science ®Google Scholar
• Pham CT. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol. 2006;6(7):541–550.
   PubMed Web of Science ®Google Scholar
• Temmesfeld-Wollbrueck B, Heinrichs C, Szalay A, et al. Granulomatous gastritis in Wegener's disease: differentiation from Crohn's disease supported by a positive test for antineutrophil antibodies. Gut. 1997;40(4):550–553.
   PubMed Web of Science ®Google Scholar
• Vaszar LT, Orzechowski NM, Specks U, et al. Coexistent pulmonary granulomatosis with polyangiitis (Wegener granulomatosis) and Crohn disease. Am J Surg Pathol. 2014;38(3):354–359.
   PubMed Web of Science ®Google Scholar
• Humbert S, Guilpain P, Puechal X, on behalf of the French Vasculitis Study Group, et al. Inflammatory bowel diseases in anti-neutrophil cytoplasmic antibody-associated vasculitides: 11 retrospective cases from the French Vasculitis Study Group. Rheumatology. 2015;54(11):1970–1975.
   PubMed Web of Science ®Google Scholar
• Dobric S, Popovic D, Nikolic M, et al. Anti-neutrophil cytoplasmic antibodies [ANCA] specific for one or several antigens: useful markers for subtypes of ulcerative colitis and associated primary sclerosing cholangitis. Clin Chem Lab Med. 2011;50:503–509.
   PubMed Web of Science ®Google Scholar
• Locht H, Skogh T, Wiik A. Characterisation of autoantibodies to neutrophil granule constituents among patients with reactive arthritis, rheumatoid arthritis, and ulcerative colitis. Ann Rheum Dis. 2000;59(11):898–903.
   PubMed Web of Science ®Google Scholar
• Elzouki AN, Eriksson S, Löfberg R, et al. The prevalence and clinical significance of α1-antitrypsin deficiency [PiZ] and anca specificities. Inflamm Bowel Dis. 2007;5(4):246–252.
   Web of Science ®Google Scholar
• Taddei C, Audrain MA, Reumaux D, et al. Alpha1-antitrypsin phenotypes and anti-neutrophil cytoplasmic auto-antibodies in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1999;11:1293–1298.
   PubMed Web of Science ®Google Scholar
• Walmsley RS, Zhao MH, Hamilton MI, et al. Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease. Gut. 1997;40(1):105–109.
   PubMed Web of Science ®Google Scholar
• Abad E, Tural C, Mirapeix E, et al. Relationship between ANCA and Clinical Activity in Inflammatory Bowel Disease: Variation in Prevalence of ANCA and Evidence of Heterogeneity. J Autoimmun. 1997;10(2):175–180.
   PubMed Web of Science ®Google Scholar
• Aitola P, Miettinen A, Mattila A, et al. Effect of proctocolectomy on serum antineutrophil cytoplasmic antibodies in patients with chronic ulcerative colitis. J Clin Pathol. 1995;48(7):645–647.
   PubMed Web of Science ®Google Scholar
• Castellino F, Rosina F, Bansi DS, et al. Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease: Do they recognize different subsets of a heterogeneous disease? Eur J Gastroenterol Hepatol. 1995;7:859–864.
   PubMed Web of Science ®Google Scholar
• Hertervig E, Wieslander J, Johansson C, et al. Anti-Neutrophil Cytoplasmic Antibodies in Chronic Inflammatory Bowel Disease: Prevalence and Diagnostic Role. Scand J Gastroenterol. 1995;30(7):693–698.
   PubMed Web of Science ®Google Scholar
• Peen E, Almer S, Bodemar G, et al. Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease. Gut. 1993;34(1):56–62.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Reumaux D, Duthilleul P, et al. Antineutrophil cytoplasmic autoantibodies in inflammatory bowel diseases. Gastroenterol Clin Biol. 1992;16(8-9):656–660.
   PubMedGoogle Scholar
• Cambridge G, Rampton DS, Stevens TR, et al. Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1992;33(5):668–674.
   PubMed Web of Science ®Google Scholar
• Rump JA, Roth M, Schölmerich J, et al. A new type of ANCA in sera of patients with ulcerative colitis: effects of therapy and disease severity on serum titer. Immun Infekt. 1992;20(1):16–18.
   PubMedGoogle Scholar
• Rump JA, Scholmerich J, Gross V, et al. A new type of Perinuclear Anti-Neutrophil Cytoplasmic Antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology. 1990;181(4-5):406–413.
   PubMed Web of Science ®Google Scholar
• Horn MP, Peter AM, Righini Grunder F, et al. PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn’s disease. PLoS One. 2018;13(12):e0208974.
   PubMed Web of Science ®Google Scholar
• Yang P, Bohr J, Tysk C, et al. Antineutrophil cytoplasmic antibodies in inflammatory bowel disease and collagenous colitis: no association with lactoferrin, β-glucuronidase, myeloperoxidase, or proteinase 3. Inflamm Bowel Dis. 1996;2(3):173–177.
   PubMed Web of Science ®Google Scholar
• Van Biervliet S, Bonroy C, Vande Velde S, et al. C-ANCA/proteinase 3-positive colitis in children: a distinctive form of inflammatory bowel disease or vasculitis with colitis as initial presentation? J Pediatr Gastroenterol Nutr. 2013;57(4):489–492.
   PubMed Web of Science ®Google Scholar
• Arias-Loste MT, Bonilla G, Moraleja I, et al. Presence of Anti-proteinase 3 Antineutrophil Cytoplasmic Antibodies [Anti-PR3 ANCA] as Serologic Markers in Inflammatory Bowel Disease. Clinic Rev Allerg Immunol. 2013;45(1):109–116.
   PubMed Web of Science ®Google Scholar
• Mahler M, Damoiseaux J, Ballet V, et al. PR3-anti-neutrophil cytoplasmic antibodies [ANCA] in ulcerative colitis. Clin Chem Lab Med. 2017;56:e27–e30.
   PubMed Web of Science ®Google Scholar
• Peter AM, Reznik D, Horn MP, et al. Diagnostic and prognostic value of auto and anti-microbial antibody profiles in paediatric inflammatory bowel disease patients. J Pediatr Gastr Nutr. 2016;62:321.
   Google Scholar
• Hoff N, Horn MP, Schibli S, et al. Anti-exocrine pancreatic and proteinase-3 antineutrophil cytoplasmic antibodies in paediatric patients with inflammatory bowel disease-a single center experience. Swiss Med Wkly. 2014;144:20S.
   Web of Science ®Google Scholar
• Mahler M, Bogdanos DP, Pavlidis P, et al. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease. Clin Chim Acta . 2013;424:267–273.
   PubMed Web of Science ®Google Scholar
• Stinton L, Kaplan G, Mahler M, et al. Proteinase 3 [PR3] autoantibodies as a serological marker in inflammatory bowel disease [IBD]. Am J Gastroenterol. 2013;108:S523.
   Web of Science ®Google Scholar
• Mahler M, Seaman A, Bogdanos DP, et al. PR3-ANCA in inflammatory bowel disease is restricted to ulcerative colitis and associated with perinuclear ANCA [PANCA] staining pattern. Clin Exp Immunol. 2011;164:90.
   PubMed Web of Science ®Google Scholar
• Rojas G, Siegel F, Jorquera J, et al. Antineutrophil cytoplasmic antibodies and nonspecific ulcerative colitis. Rev Med Chil. 1996;124(4):449–455.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang S, Lv H, et al. Does PR3-ANCA positive ulcerative colitis represent a novel subset? J Crohns Colitis. 2016;10:S185.
   Web of Science ®Google Scholar
• Liu X, Yu T, Zhao M, et al. The diagnostic significance of antineutrophil cytoplasmic antibodies in ulcerative colitis. Ch J Int Med. 1999;38:451–454.
   PubMedGoogle Scholar
• Ooi CJ, Lim BL, Cheong WK, et al. Antineutrophil cytoplasmic antibodies [ANCAs] in patients with inflammatory bowel disease show no correlation with proteinase 3,lactoferrin, myeloperoxidase, elastase, cathepsin G and lysozyme: a Singapore study. Ann Acad Med Singap. 2000;29:704–707.
   PubMedGoogle Scholar
• Takedatsu H, Mitsuyama K, Fukunaga S, et al. Diagnostic and clinical role of serum proteinase 3 antineutrophil cytoplasmic antibodies in inflammatory bowel disease. J Gastroenterol Hepatol. 2018;33(9):1603–1607.
   Web of Science ®Google Scholar
• Hamada K, Yoshino T, Sono M, et al. Clinical signifcance of anti-neutrophil cytoplasmic antibodies to proteinase-3 [PR3-ANCA] in patients with ulcerative colitis. Am J Gastroenterol. 2018;113:S26.
   Web of Science ®Google Scholar
• Xu J, Yang CH, Chen XY, et al. A subset of ulcerative colitis with positive proteinase-3 antineutrophil cytoplasmic antibody. World J Gastroenterol. 2008;14(45):7012–7015.
   PubMed Web of Science ®Google Scholar
• Sono M, Yoshino T, Yazumi S. P291 Proteinase 3-antineutrophil cytoplasmic antibodies [PR3-ANCA] would be a predictive biomarker for the clinical course of ulcerative colitis. J Crohns Colitis. 2017;11(suppl_1):S225–S225.
   Google Scholar
• Magro F, Gionchetti P, Eliakim R, European Crohn’s and Colitis Organisation [ECCO], et al. Third european evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649–670.
   PubMed Web of Science ®Google Scholar
• Gomollón F, Dignass A, Annese V, ECCO, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3–25.
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–1629.
   PubMed Web of Science ®Google Scholar
• Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 (Suppl A):5A–36A.
   PubMed Web of Science ®Google Scholar
• Mahler M, Radice A, Yang W, et al. Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. Clin Chim Acta. 2012;413(7-8):719–726.
   PubMed Web of Science ®Google Scholar
• Abu-Freha N, Badarna W, Sigal-Batikoff I, et al. ASCA and ANCA among Bedouin Arabs with inflammatory bowel disease, the frequency and phenotype correlation. BMC Gastroenterol. 2018;18(1):153–158.
   PubMed Web of Science ®Google Scholar
• Calhan T, Senateş E, Cebeci E, et al. A comparison of antineutrophil cytoplasmic antibody prevalence in patients treated and untreated for hyperthyroidism. Endocrine. 2010;38(2):199–205.
   PubMed Web of Science ®Google Scholar
• Tetikkurt C, Yuruyen M, Tetikkurt S, et al. Propylthiouracil-induced lupus-like or vasculitis syndrome. Multidiscip Respir Med. 2012;7(1):14.
   PubMed Web of Science ®Google Scholar
• Chen Y, Bao H, Liu Z, et al. Clinico-pathological features and outcomes of patients with propylthiouracil-associated ANCA vasculitis with renal involvement. J Nephrol. 2014;27(2):159–164.
   PubMed Web of Science ®Google Scholar
• Coster A, Dargent JL, de Visscher N, et al. [Pyoderma gangrenosum associated with anti-proteinase 3 antineutrophil cytoplasmic antibodies (PR3-ANCA) induced by propylthiouracil. Ann Dermatol Venereol. 2017;144(5):368–373.
   PubMed Web of Science ®Google Scholar
• Hirono H, Watanabe K, Hasegawa K, et al. A case of right-sided ulcerative colitis with mesalamine-induced hypersensitivity reactions. Am J Case Rep. 2018;19:623–629.
   PubMed Web of Science ®Google Scholar
• Unnikrishnan A, Azodi S, Ansari N, et al. PR3ANCA related cerebral vasculitis in ulcerative colitis presenting with orbital involvement: a case report with review of literature. Case Rep Rheumatol. 2014;2014:582094.
   PubMedGoogle Scholar
• Kirito Y, Yamamoto D, Uchiyama T. Proteinase 3-antineutrophil cytoplasmic antibody-positive ulcerative colitis presenting with abducens neuropathy. BMJ Case Reports. 2017;2017:1757–1790.
   Google Scholar